- Home
- SCLXW vs CYCN Comparison
SCLXW vs CYCN Comparison
Compare SCLXW & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- CYCN
- Stock Information
- Founded
- SCLXW N/A
- CYCN 2018
- Country
- SCLXW United States
- CYCN United States
- Employees
- SCLXW 113
- CYCN N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- SCLXW Health Care
- CYCN Health Care
- Exchange
- SCLXW Nasdaq
- CYCN Nasdaq
- Market Cap
- SCLXW N/A
- CYCN N/A
- IPO Year
- SCLXW 2021
- CYCN N/A
- Fundamental
- Price
- SCLXW $0.21
- CYCN $3.32
- Analyst Decision
- SCLXW
- CYCN
- Analyst Count
- SCLXW 0
- CYCN 0
- Target Price
- SCLXW N/A
- CYCN N/A
- AVG Volume (30 Days)
- SCLXW N/A
- CYCN 9.1M
- Earning Date
- SCLXW N/A
- CYCN 11-14-2024
- Dividend Yield
- SCLXW N/A
- CYCN N/A
- EPS Growth
- SCLXW N/A
- CYCN N/A
- EPS
- SCLXW N/A
- CYCN N/A
- Revenue
- SCLXW N/A
- CYCN $194,000.00
- Revenue This Year
- SCLXW N/A
- CYCN N/A
- Revenue Next Year
- SCLXW N/A
- CYCN N/A
- P/E Ratio
- SCLXW N/A
- CYCN N/A
- Revenue Growth
- SCLXW N/A
- CYCN N/A
- 52 Week Low
- SCLXW N/A
- CYCN $1.27
- 52 Week High
- SCLXW N/A
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- CYCN 51.52
- Support Level
- SCLXW N/A
- CYCN $3.15
- Resistance Level
- SCLXW N/A
- CYCN $3.79
- Average True Range (ATR)
- SCLXW 0.00
- CYCN 1.03
- MACD
- SCLXW 0.00
- CYCN -0.02
- Stochastic Oscillator
- SCLXW 0.00
- CYCN 21.79
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.